Evaluation of medicines advertising in medical journals

Authors

  • Daliana Maria Berenice de Oliveira Souza Federal University of Rio Grande do Norte; Health Sciences Center; Department of Pharmacy; Laboratory of Advertising Monitoring for Products Subject to Health Surveillance
  • Suellen Cristiane Medeiros de Lima Federal University of Rio Grande do Norte; Health Sciences Center; Department of Pharmacy; Laboratory of Advertising Monitoring for Products Subject to Health Surveillance
  • Almária Mariz Batista Federal University of Rio Grande do Norte; Health Sciences Center; Department of Pharmacy; Laboratory of Advertising Monitoring for Products Subject to Health Surveillance
  • Maria Cleide Ribeiro Dantas de Carvalho Federal University of Rio Grande do Norte; Health Sciences Center; Department of Pharmacy; Laboratory of Advertising Monitoring for Products Subject to Health Surveillance

DOI:

https://doi.org/10.1590/S1984-82502009000200016

Keywords:

Medicines^i1^sadvertis, Medicines^i1^sprescript, Medicines^i1^slegislat

Abstract

This work intended to analyze the advertising of medicines requiring medical prescription, divulged into three journals of the neurology and cardiology areas addressed to healthcare professionals. The analysis was based on current legislation, among other criteria, as well as specific literature. The presence of the following items was investigated: registration number, drug name, specific indications, contraindications; cautions and warnings; adverse reactions; possible side effects; posology; legibility of technical-scientific information and bibliographic references, phrases and/or expressions about the medication benefits, as compared to other drugs; safety warnings, healing promises and pictures of people smiling, and the quotations confirmation based on bibliographic references. Among the evaluated legal criteria, it was observed the absence of legibility in technical-scientific information in 85% of advertisements; absence of side effects in 23%; absence of cautions and warnings in 15%; of contraindications in 12.8%; of posology in 6.4%; of registration numbers in 2.7% and of the Common Brazilian Denomination/Common International Denomination (Denominação Comum Brasileira/Denominação Comum Internacional - DCB/DCI) in 0.6%. Out of 130 statements respecting advantages face to others drugs, 23.8% were not confirmed and out of 48 divulged safety messages, 41.7% could not be found in quoted references. The pictures of people smiling was a resource used in 42.2% of advertisements. Out of 1362 references analyzed, 19.7% were not found and 37.1% of quoted affirmations weren't confirmed.

Downloads

Download data is not yet available.

Downloads

Published

2009-06-01

Issue

Section

Original Papers

How to Cite

Evaluation of medicines advertising in medical journals . (2009). Brazilian Journal of Pharmaceutical Sciences, 45(2), 303-312. https://doi.org/10.1590/S1984-82502009000200016